COVID-19 and Clinical Trials: The Medidata Perspective
COVID-19 and Clinical Trials: The Medidata Perspective
Release 9.0
As the global impact of COVID-19 increases, Medidata is continuously analyzing its effect on patient study enrollment, the response by world regulatory bodies and which Medidata’s solutions can help address your COVID 19-related challenges. Read our latest report.
COVID-19 and Clinical Trials:
The Medidata Perspective
Introduction
As COVID-19 has spread, we have been monitoring its global impact on clinical trials. We see the profound impact on our industry, both at a global level but also at the site level. Understanding what is happening on the ground is critical to define a path forward. Sharing this data is an important step, but it’s a first step. We will continue to publish updated analyses on overall industry trends throughout this pandemic and beyond.